Nintedanib Arrow (Nintedanib)

Nintedanib blocks several receptor tyrosine kinases—VEGFR, PDGFR, and FGFR—thereby inhibiting signals that promote fibroblast growth, new blood‑vessel formation, and tissue remodeling. This multi‑target inhibition reduces fibrotic tissue buildup in the lungs and limits the vascular support that tumors need to grow.

The specific dose and dosing schedule for Nintedanib Arrow are determined by the prescribing clinician based on the patient’s condition, weight, renal and hepatic function, and other individual factors. Healthcare professionals should follow the product label and local prescribing guidelines.

The safety of Nintedanib Arrow in pregnancy and lactation has not been established. It is classified as pregnancy category unknown, and the drug should only be used if the potential benefit justifies the potential risk to the fetus. Breastfeeding mothers should consult their physician before using the medication.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements) and necessary import documentation.

Nintedanib differs from other antifibrotics such as pirfenidone by targeting a broader range of tyrosine kinases, which may provide additional benefit in certain fibrotic pathways. Clinical trials have shown comparable efficacy in slowing lung‑function decline, but the side‑effect profile and drug‑interaction potential vary, so choice of therapy should be individualized.

Nintedanib Arrow should be stored at ambient temperature, below 25 °C, in its original packaging to protect it from moisture and excessive heat. Keep the product out of direct sunlight and away from sources of humidity.

Nintedanib Arrow is taken orally, usually as a whole tablet swallowed with water. The medication is typically taken with food to reduce gastrointestinal discomfort, but patients should follow the specific instructions provided by their healthcare professional.

Serious risks include severe liver injury, major bleeding events, gastrointestinal perforation, and significant hypertension or arterial thromboembolism. Patients should be monitored regularly for signs of these complications, and therapy should be discontinued if any life‑threatening adverse event occurs.

Nintedanib Arrow is contraindicated in patients with severe hepatic impairment (Child‑Pugh C), active uncontrolled bleeding, or known hypersensitivity to nintedanib or any of the tablet excipients. Caution is also advised for individuals with significant cardiovascular disease or a history of gastrointestinal ulcers.